去纤苷使用量是多少？

Defibrotide (defiteli) has received marketing authorization from the European Commission for the treatment of severe hepatic VOD in hematopoietic stem cell transplantation (HSCT). A phase 3 randomized controlled trial of defibrotide (defiteli) for the prevention of hepatic VOD in pediatric transplant patients has also been completed. Defibrotide (defiteli) has been generally well tolerated; the most common adverse reactions observed during premarketing use to treat hepatic VOD were bleeding, hypotension, and coagulopathy. 

Recommended dose: The recommended dose of defibrotide (defiteli) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. This dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give defiteli for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defiteli until resolution of VOD or up to a maximum of 60 days. 2. Dosing Instructions: Defiteli must be diluted before infusion; before administration of defiteli, confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable to no more than one vasopressor, constant over a 2-hour period. Administer defibrotide (defiteli, defiteli) by intravenous infusion; use an infusion set equipped with a 0.2 micron in-line filter to administer a diluted deferbide (defiteli, defiteli) solution. Use 5% glucosamine injection, USP or 0.9% sodium chloride injection, USP immediately before and after administration. Flush the intravenous administration line (peripheral or central). Do not coadminister defibrotide (defiteli) with other intravenous medications at the same time and in the same intravenous line.